Homozygous 40-to go-day-old
derived from the C57BL/6J strain, have been used to set up an in uivo body weight gain bioassay for GH whose performance has been compared to the widely used hypophysectomized rat assay. A log dose-response curve has been analyzed in order to choose doses in the linear range that are suitable for setting up useful, precise, and economical 2 x 2 factorial assays. A comparison between the response in the two sexes has also been carried out, showing no significant difference between male and female little mice of this age.
Three Standard of GH (human) for bioassay @O/505), stated that the in vivo weight gain assay was probably the defining test for hGH determination (5, 6). Following this principle, Groesback and Parlow (7) carried out an extensive study on the principal factors influencing the precision of this assay, obtaining more reliable and consistent values for the index of precision (X) of the order of 0.2, a value considered highly respectable. More recently, however, with the increasing utilization of recombinant human GH (hGH), there have been repeated calls to abandon this bioassay as a routine control procedure for GH due to the fact that the method is highly invasive, imprecise, and costly as well as to the increasing pressure against animal use (8). The assay, however, should remain as an unsubstitutable bioidentity test (9, lo), especially for the characterization and validation of the manufacturing process (11, 12). Having carried out in viva hGH bioassays in our laboratory during the last 15 yr (13, 14), we were aware of the need for an alternative animal model that while still measuring pa-rameters of linear growth, does not require such laborious, costly, and time-consuming surgery as hypophysectomy. The model we have investigated is the "little" mouse, an autosoma1 recessive mutant from the C57BL/6J strain, noted and produced by Jackson Laboratory (Bar Harbor, ME), in which an inherited growth defect appears to resemble human isolated GH deficiency type I (15-l 7).
These mutants (lit/lit), males and females, whose weight at 30 days of age is approximately 60% that of normal mice, were studied with regard to hGH dose-response relationship in a BWG assay to choose useful and economical doses within the linear range of the curve. Little mice were then used in different 2 x 2 factorial assay designs for the calibration of a secondary hGH standard compared with the classical BWG assay in hypophysectomized rats. Aspects related to sensitivity, precision, accuracy, and economy of this new bioassay were also studied. as X'L = C* M' + t C sM, where M' is the log10 of determined relative potency of the unknown, t is the Student's t for P = 0.05, sM is the SE of M', and C is calculated according to C* = BZ/(B2 -s't'), where BZ is the variance related to the combined slope of the dose-response curve. The convention adopted (3) was to define an x-day assay as the design in which the animals are injected for x -1 days, without weekend interruption, weighing them for the last time on the xth day.
Sensitivity determination
The sensitivity calculation was based on the response and SD at zero and the minimal dose administered, according to Rodbard's definition (20) .
Results
The growth curves of male and female little mice (lit/lit) compared with those of their heterozygous litter mates (lit/ +) in our laboratory are presented in Fig. 1 . The data are in good agreement with literature values (15); the body weight of little mice was about 60% that of their heterozygous littermates at the age of 4 weeks and about 45% after lo-11 weeks of age. It is interesting to note that there was a significant difference between males and females (P = 0.05) in both heterozygous and little mouse growth curves after 4 weeks of age.
The difference in response between male and female little mice at 45-90 days of age treated with the same dose of hGH (24 pg/day) was tested in separate assays (Table 1 ) and found to be nonsignificant in both single and cumulative t tests (P = 0.05), confirming the data presented by Beamer and Either (21) with higher doses of GH (ovine) and for a much longer treatment period (6 weeks). A dose-response curve was, therefore, carried out at the dosage levels of 5, 10, 20, and 50 pg/day, using a mixed population of males and females of the same age and comparing their weight increases to values previously obtained with hypophysectomized rats using the same hGH preparation (Second Brazilian Standard) in approximately the same dose range ( Fig. 2A) . Both curves exhibited good linearity in the range usually used in our assays; the correlation coefficients for rats and mice were, respectively, r = 0.9862 and r = 0.9996. To represent rat and mice dose-response curves in the same figure, two different ordinate scales were necessary, one lofold more expanded than the other. Since the little mice used in our assays normally weigh about one tenth of our hypophysectomized rats, we considered this artificial presentation to be proper and quite practical for the purpose of a comparison between the two different animal models. In Fig. 2B , the same dose-response relationship is presented, not as the direct weight increase, but as its percentage, calculated based on the animal weights on assay day 1. There was a significantly higher percent response in little mice and a good parallelism between the two curves; the slopes for the rat and mice curves were, respectively, 3.6% and 3.3% weight curve determined at the dosage levels of 5, 10, 20, and 50 pg/mouse.day and 12, 24, and 50 pg/hypophysectomized rat. day, always using the same hGH preparation (Second Brazilian Standard).
A, Direct weight increase; B, percent weight increase.
increase/in dose. Sensitivity, determined using the data of this dose-response curve, was 1.10 &mouse. day (P = 0.05). In this and all other assays, a control group was always included, although it is not required in the 2 X 2 factorial assay statistical calculations. The average daily weight increase during the assay of these untreated little mice (n = 45 animals distributed in four different assays) was x = 0.010 + 0.068 g/day, while the smallest dose (5 pg/day) provoked an average increase of x = 0.118 f 0.024 g/day.
On the basis of these data, we set up 2 X 2 factorial assays in little mice for comparison with the classical assay that uses female hypophysectomized rats, again using the same two hGH preparations, WHO International Standard 80/505 and Second Brazilian Secondary Standard. The results of these four assays are presented in Table 2 . There was good interassay agreement in the potency values (x = 2.44 f 0.26 IU/ mg; coefficient of variation, 10.6% for n = 4) and a comparable precision between the rat and mouse assays, as noted from the values of X and the fiducial limits, all acceptable according to an official definition (22). In the same table, the average values of all correlation coefficients relative to the growth curves (body weight us. bioassay day) of all animals (n = 40/assay) are also reported, showing a linearity in growth for the little mice at least as good as that presented for female hypophysectomized rats. Not shown are the results obtained for 4-day instead of 5-day assays, a modification that, among other factors, requires 25% less of the hormone preparations. This more economical design was still perfectly valid, increasing the index of precision to only 7%, while maintaining the acceptability of the fiducial limits.
Finally, Table 3 summarizes the most significant statistical parameters obtained in the last 10 bioassays carried out in our laboratory via the BWG assay in hypophysectomized rats for the potency determination of different pituitary extracts, using throughout 2 X 2 factorial assay designs, 40 animals, and the same standard preparation (WHO 80/505) at lo-and 20-pg daily doses. The precision of the new bioassay in little mice is perfectly comparable to that obtained, after years of experience, with the classical assay. From a strictly economical point of view, without including labor and material due to rat surgery (2-3 men/week. assay), we estimate the cost to be about 10 times lower for our animal house, due mainly to the lower cost of breeding and conditioning of little mice compared to rats.
Discussion
The little mice proved to be a valid alternative model to the BWG assay in hypophysectomized rats. They provide a faster, cheaper, and noninvasive in vim assay for the potency and bioidentity determination of hGH extracts, allowing the utilization of male and female mice, 45-90 days of age, in lo-day or, better still, 5-or 4-day assays. These animals, after hGH administration, exhibit a higher percent weight increase than hypophysectomized rats, equal or better linear growth, and a useful range of the dose-response curve. Precision, with a perfectly acceptable index (X) of 0.20-0.25, was also at least as good as that presented by the classical assay; the fiducial limits were all acceptable according to the criteria established by the European Pharmacopoeia. Moreover, considering all of the data obtained in our laboratory with the hypophysecomized rat BWG assay using the same assay design and International Standard for GH, human (WHO 80/505), the statistical data obtained with the little mice assay confirm the quality and good performance of this new bioassay in a much wider comparison.
The potency of a Secondary Standard preparation determined against the International Standard provided comparable values in the two animal models, indicating a similar accuracy for the two in vim tests. The assay sensitivity also presented a better value than the 1.99 &day obtained in previous work (14) for hypophysectomized rats and apparently also higher than that presented by Holder et al. (23) in their study in Snell dwarf mice, which was the basis for a bioassay for GH. These researchers studied this amimal model, later characterized with a single autosomal recessive point mutation in the pit-l gene (24), with repect to three growth parameters: body weight increase, tail length increase, and uptake of 35S04-2 into costal cartilage in vim.
Although there was a high correlation between these growth responses and hGH, they did not carry out real bioassays; the body weight increase was significantly greater than the control value only at a dose of 41.6 mIU/day (-12-15 pg purified hGH/day) after a treatment period of 21 days. The fact that high sensitivities can be attained with little mice is probably related to the stability in weight shown by the control groups. With respect to the different assay designs studied in this work, although we used the lo-day assay (one injection per day) mainly for the purpose of comparison with an identical design carried out over years in hypophysectomized rats, we prefer a 5-or even a 4-day assay (two injections per day), especially useful when fast determinations are required and with practically no loss in precision.
In conclusion, besides being practical and economical, the little mouse assay offers two incomparable advantages for in vim BWG assays: no need for surgery and the possibility of assaying somatotropic preparations in a model strictly resembling human isolated GH deficiency type I. For these reasons, we have decided to include it among our assays in a recent WHO International Collaborative Study of the Proposed Standard for Recombinant Human Growth Hormone, where the little mouse assay was used for the calculation of the unweighted geometric mean of laboratory mean estimates by in viva BWG bioassay (to be published on behalf of the National Institute for Biological Standards and Control-WHO, South Mimms, Potters Bar, United Kingdom).
